Skip to main content

Table 4 Proposed and marketed urinary tests for bladder cancer screening: summary of performance, availability, acceptability, adverse effects

From: Medical follow-up for workers exposed to bladder carcinogens: the French evidence-based and pragmatic statement

Test/dosage Sensitivity Specificity Main references
Detection of haematuria using a reactive test strip 46 to 74% for one test, If test repeated over several days: 90 to 95% 51 to 84% [190, 198202]
Urinary cytology ▪ For all tumour grades and stages: 44% [CI 95%, 38–51] [203] ▪ For all tumour grades and stages: 96% [CI 95%, 94–98][203] [191197, 203, 204]
For Carcinoma in situ (Cis) 70 to 90% ▪ For Cis: 90%
NMP22BC test ▪ For all tumour grades and stages: 65% [CI 95%, 50–80] [203] ▪ For all tumour grades and stages: 81% [CI 95%, 50–85] [203] [197, 203209]
- NMIBC: 81.8%
- MIBC: 57.1%
- Grade G1: 83.9%
- Grade G3: 62.5%
Fluorescence immunocytochemistry (ImmunoCyt™/uCyt + ™) ▪ For all tumour grades and stages: 84% [CI 95%, 77–91] [203] ▪ For all tumour grades and stages: 75% [CI 95%, 68–83] [203] [189, 203, 210213]
FISH (Fluorescence In Situ Hybridisation) UroVysion™ Kit ▪ For all tumour grades and stages: 76% [CI 95%, 65–84] [203] ▪ For all tumour grades and stages: 75% [CI 95%, 78–92] [203] [189, 191, 192, 203, 214218]
For Cis and G3: >95%